Evaluation by Q-RTPCR of the efficacy of ribavirin complexed with beta-cyclodextrin against measles virus in a mouse encephalitis model

Pathologie Biologie

Volumn 54, Issue 10, 2006, Pages 541-544

  Jeulin, H ^a   Grancher, N ^a,c   Kedzierewicz, F ^b   Le Faou, A E ^a   Venard, V ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b NANCY UNIVERSITÉ   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

cyclodextrin; Encephalitis; Measles Virus; Murin model; Ribavirin

Indexed keywords

BETA CYCLODEXTRIN; DRUG CARRIER; OLIGOSACCHARIDE; RIBAVIRIN; WATER; ANTIVIRUS AGENT; BETA CYCLODEXTRIN DERIVATIVE;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; ENCEPHALITIS; IN VITRO STUDY; MEASLES VIRUS; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; CBA MOUSE; DISEASE MODEL; DRUG COMBINATION; MEASLES; VIRUS ENCEPHALITIS;

ANIMALS; ANTIVIRAL AGENTS; BETA-CYCLODEXTRINS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENCEPHALITIS, VIRAL; MEASLES; MEASLES VIRUS; MICE; MICE, INBRED CBA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN;

EID: 33751236798     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.07.008     Document Type: Article

References (19)

1. Huffman J.H., Sidwell R.W., Khare G.P., Witkowski J.T., Allen L.B., and Robins R.K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob. Agents Chemother. 3 2 (1973) 235-241
2. Forni A.L., Schluger N.W., and Roberts R.B. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin. Infect. Dis. 19 3 (1994) 454-462
3. Hosoya M., Mori S., Tomoda A., Mori K., Sawaishi Y., Kimura H., et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob. Agents Chemother. 48 12 (2004) 4631-4635
4. Schneider-Schaulies S., and ter Meulen V. Measles virus and immunomodulation: molecular bases and perspectives. Expert. Rev. Mol. Med. (2002) 1-18
5. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 3 2 (2003) 90-105 (51)
6. Gilbert B.E., and Wyde P.R. Pharmacokinetics of ribavirin aerosol in mice. Antimicrob. Agents Chemother. 32 1 (1988) 117-121
7. Honda Y., Hosoya M., Ishii T., Shigeta S., and Suzuki H. Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters. Antimicrob. Agents Chemother. 38 4 (1994) 653-655
8. Zhang M.-Q., and Rees D.C. A review of recent applications of cyclodextrins for drug discovery. Expert Opinion on Therapeutic Patents 9 (1999) 1697-1717
9. Nicolazzi C., Venard V., Le Faou A., and Finance C. In vitro antiviral efficacy of the ganciclovir complexed with beta-cyclodextrin on human cytomegalovirus clinical strains. Antiviral Res. 54 2 (2002) 121-127
10. Grancher N., Kedzierewicz F., Venard V., Marsura A., Finance C., and Le Faou A. Physicochemical Study of Ribavirin Complexes with alpha-, bêta- and gamma-Cyclodextrins. J. Incl. Phenom. Macroc. Chem. 51 (2005) 149-157
11. Grancher N., Venard V., Kedzierewicz F., Ammerlaan W., Finance C., Muller C.P., et al. Improved antiviral activity in vitro of ribavirin against measles virus after complexation with cyclodextrins. Antiviral Res. 62 3 (2004) 135-137
12. Chavanpatil M.D., and Vavia P.R. The influence of absorption enhancers on nasal absorption of acyclovir. Eur. J. Pharm. Biopharm. 57 3 (2004) 483-487
13. Uhlmann V., Martin C.M., Sheils O., Pilkington L., Silva I., Killalea A., et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol. Pathol. 55 2 (2002) 84-90
14. Tilloy S., Monnaert V., Fenart L., Bricout H., Cecchelli R., and Monflier E. Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier. Bioorg. Med. Chem. Lett. 16 8 (2006) 2154-2157
15. Neighbour P.A., Rager-Zisman B., and Bloom B.R. Susceptibility of mice to acute and persistent measles infection. Infect. Immun. 21 3 (1978) 764-770
16. Monnaert V., Tilloy S., Bricout H., Fenart L., Cecchelli R., and Monflier E. Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. J. Pharmacol. Exp. Ther. 310 2 (2004) 745-751
17. Elbeik T., Charlebois E., Nassos P., Kahn J., Hecht F.M., Yajko D., et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J. Clin. Microbiol. 38 3 (2000) 1113-1120
18. Tang G.P., Guo H.Y., Alexis F., Wang X., Zeng S., Lim T.M., et al. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. J. Genet. Med. 8 6 (2006) 736-744
19. Zheng Y., Zuo Z., and Chow A.H. Lack of effect of beta-cyclodextrin and its water-soluble derivatives on in vitro drug transport across rat intestinal epithelium. Int. J. Pharm. 309 1-2 (2006) 123-128